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Abstract
The present study examined the effects of the mGluR1 antagonist JNJ16259685 (JNJ) and the
mGluR5 antagonist MPEP alone and in combination with morphine in two acute pain models
(hotplate, warm water tail-withdrawal), and a persistent, inflammatory pain model (capsaicin). In
the hotplate and warm water tail-withdrawal procedures, JNJ and MPEP were ineffective when
administered alone. In both procedures, JNJ potentiated morphine antinociception. In the hot plate
procedure, MPEP potentiated morphine antinociception at the highest dose examined, whereas in
the warm water tail-withdrawal procedure MPEP attenuated morphine antinociception at a
moderate dose and potentiated morphine antinociception at a high dose. For both JNJ and MPEP,
the magnitude of this morphine potentiation was considerably greater in the hotplate procedure. In
the capsaicin procedure, the highest dose of MPEP produced intermediate levels of
antihyperalgesia and also attenuated the effects of a dose of morphine that produced intermediate
levels of antihyperalgesia. In contrast, JNJ had no effect when administered alone in the capsaicin
procedure and did not alter morphine-induced antihyperalgesia. The present findings suggest that
the effects produced by mGluR1 and mGluR5 antagonists alone and in combination with
morphine can be differentiated in models of both acute and persistent pain.
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INTRODUCTION
Evidence indicates that the excitatory amino acid glutamate is involved in both pain
processing and the modulation of mu opioid-induced antinociception and antihyperalgesia
(e.g., Mao, 1999; Kozela et al., 2003). Indeed, antagonists at the N-methyl-d-aspartate
(NMDA) receptor site produce antihyperalgesic effects in most persistent or chronic pain
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models (Chaplan et al., 1997). Although NMDA antagonists do not produce antinociception
in acute pain models when administered alone (Nemmani et al., 2004), they either potentiate
or antagonize the antinociceptive effects of morphine and other mu opioid agonists (Allen et
al., 2003; Chen et al., 2005; Fischer and Dykstra, 2006). These effects have been shown to
be dependent upon the dose of morphine, dose of the NMDA antagonist, and the type of
pain model (e.g., Maeda et al., 2002; Nemmani et al., 2004; Craft and Lee, 2005).
Metabotropic glutamate (mGlu) receptor sites have also been linked to pain processing,
although reports describing the interaction of mGluR antagonists with mu opioid agonists
are limited. However, Fischer et al., (2008b) reported that in a mouse tail-flick procedure the
mGluR1 antagonist, JNJ16259685 (JNJ) and the mGlu2/3 receptor antagonist LY341495
failed to produce antinociception when administered alone, but potentiated morphine
antinociception in a dose-dependent manner. Moreover, JNJ increased the antinociceptive
efficacy of the partial mu opioid agonists buprenorphine and dezocine under conditions in
which these opioids produced less than maximal effects (Fischer et al., 2008a). There is
evidence to suggest that these effects may be indirectly mediated by activity at NMDA
receptors, as activation of mGluR receptors enhances NMDA receptor activity (Kelso et al.,
1992; Skeberdis et al., 2001). In contrast, the mGluR5 receptor antagonist MPEP has not
been shown to produce antinociception nor does it alter morphine antinociception (Fischer et
al., 2008a).
Considerably less is known about the effects of mGluR antagonists in models of persistent
or chronic pain. mGluR2/3 and mGluR5 antagonists do, however, attenuate hyperalgesia
induced by the administration of inflammatory agents (Simmons et al., 2002; Sevostianova
and Danysz, 2006), and this finding is supported by studies indicating that mGluR receptors
are present on peripheral terminals of primary sensory neurons (Walker et al., 2001b; Yang
and Gereau, 2002) and are up-regulated in response to acute or persistent inflammation
(Dolan et al., 2003). Moreover, in models of persistent inflammatory pain and a neuropathic
pain model, some mGluR1 antagonists enhance morphine-induced antihyperalgesia (Yoon
et al., 2006; Osikowicz et al., 2008). Similarly, knockdown of mGlu1 receptors increases the
effectiveness of morphine in a model of neuropathic pain (Fundytus et al., 2001).
The present study was designed to examine the effects of the metabotropic glutamate
antagonists JNJ and MPEP alone and in combination with morphine in rat models of both
acute pain and persistent, inflammatory pain. JNJ and MPEP were selected for study as their
acute effects have been examined in a number of pain models (e.g., Lea and Faden, 2006;
Fischer et al., 2008a), and studies suggest that moderate doses of these compounds have
minimal effects on locomotor activity (e.g., Henry et al., 2002; Popik and Wrobel, 2002;
Hodgson et al., 2011). Such effects are critical when examining the effects of drugs in
combination with morphine, as changes in motor behavior can interfere with the assessment
of nociception.
Specifically, the effects of morphine in combination with JNJ and MPEP were examined in
both hotplate and warm water tail-withdrawal procedures as well as a capsaicin procedure
where persistent nociception and inflammation are induced by the administration of
capsaicin locally into the tail. Comparison across acute and chronic pain models is critical,
as it is well established that these models differ in terms of nociceptive duration, type of
nociceptive response, nociceptive stimulus and the presence of inflammation (Le Bars et al.,
2001). Moreover, the nociceptive response observed in acute and chronic pain models is
mediated by distinct pain fibers and subserved by distinct excitatory amino acids and
neurotransmitter systems (Le Bars et al., 2001; Kayser et al., 2007).
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Three month old male F344 rats were obtained from Charles River Laboratories (Raleigh,
NC, USA). Rats were individually housed in a colony on a 12-h/12-h light/dark cycle with
unlimited access to food and water and all experiments were performed in the light phase of
the animals’ light/dark cycle (between the hours of 10:00 and 16.00 h). Animal protocols
were approved by the Institutional Animal Care and Use Committee at the University of
North Carolina, and the methods were in accord with the guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Research, Division on Earth and Life
Studies, National Research Council, 2010).
Hotplate and Warm Water Tail-withdrawal assays
Three types of sessions were conducted: warm water tail-withdrawal alone (5.6 mg/kg JNJ/
morphine), hotplate alone (0.3 mg/kg JNJ/morphine), and warm water tail-withdrawal
immediately followed by the hotplate (all other dose combinations of JNJ/ and MPEP/
morphine). Previous studies from our laboratory (e.g., Lomas et al., 2008) indicated that
baselines values and the effects produced by various drugs do not differ when hotplate and
warm water tail-withdrawal procedures are conducted separately or sequentially. However,
when using the procedures sequentially, testing first in the hotplate altered subsequent
latencies in the warm water tail-withdrawal procedure. Consequently, in the present
investigation tests were conducted first in the warm water tail-withdrawal procedure.
For each type of session, animals were tested twice under baseline conditions to yield an
average baseline latency measure. A cumulative morphine dosing procedure was then used
to obtain a morphine dose-effect curve. The selected dose of either JNJ or MPEP was
administered once prior to obtaining each cumulative dose-effect curve, with the injections
of JNJ and MPEP administered 30 min before administering the first dose of morphine, and
each cumulative morphine dose administered 15 min prior to each test. Based on initial
results with moderate doses of JNJ, different doses of JNJ were used in the hotplate (0.3 –
3.0 mg/kg) and warm water tail-withdrawal (1.0 – 5.6 mg/kg) procedures. Tests were also
conducted with selected doses of JNJ and MPEP administered alone 15 min prior to testing,
and then re-tested at 30, 45 and 60 min.
In the warm-water tail withdrawal procedure, rats were removed from their home cages and
lightly restrained while the distal 7 cm of the tail was placed into a 52°C water bath. The tail
withdrawal latency from the water was then recorded. A cutoff limit of 15 sec (maximal
possible effect) was used to avoid tissue damage. In the hotplate procedure, rats were placed
on a hotplate analgesia meter set at 52°C (Columbus Instruments, Columbus, OH). Latency
to lick the hind paw or perform an escape response was recorded. A cutoff limit of 40 sec
(maximal possible effect) was used to prevent tissue damage.
Capsaicin Tail Withdrawal Assay
Prior to the induction of an inflammatory state, each animal was lightly restrained and the
distal 7 cm of the tail immersed in a non-noxious 45°C water bath. Animals that failed to
keep their tails in the water for a maximum of 15 sec at the beginning of a session were not
tested with drugs. Hyperalgesia was then induced by injecting 3.0 µg capsaicin 3.5 cm from
the distal end of the tail using a protocol identical to that previously used in this laboratory
(Barrett et al., 2003; Lomas et al., 2008). Animals were placed into a chamber prepared with
~1.0 mL of isoflurane and monitored for sedation. Immediately following the onset of
sedation, animals were removed from the isofluorane chamber, administered capsaicin
locally via s.c. injection in the tail, then placed back in the home cage. Rats recovered from
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the procedure within 2–3 mins. After administration of capsaicin, tail-withdrawal latencies
from the 45°C water decreased from 15 sec to approximately 4 sec (data not shown).
As the antihyperalgesic effects of capsaicin peak at 15–30 min and then decline over 1 h
(Barrett et al., 2003), cumulative dose testing could not be conducted. Consequently, during
acute drug tests rats received varying doses of morphine either alone or in selected
combinations with JNJ and MPEP. The administration of these drugs or drug combinations
preceded testing by 30 min, with capsaicin administered 15 min before testing. For all tests
of antihyperalgesia, a 15 s cutoff limit was used as a maximal antihyperalgesic effect (i.e.,
withdrawal latencies returned to pre-inflammation baseline levels). Rats were tested once
per week with no more than 5 tests per animal. The number of animals tested with JNJ and
MPEP in combination with the highest dose of morphine (10 mg/kg) was limited due to
toxic reactions.
Drugs
Morphine sulfate was provided by the National Institute on Drug Abuse (Bethesda, MD),
JNJ (Ki=0.34 nM) and MPEP (Ki=16 nM) were purchased from Tocris Biosciences
(Ellisville, MO), and isoflurane from both Phoenix Pharmaceuticals (St. Joseph, MO) and
Sigma-Aldrich, Inc. (St. Louis, MO). Morphine sulfate and MPEP were dissolved in a 0.9%
phosphate-buffered saline solution, JNJ in 45% (w/v) 2-hydroxypropyl-β-cyclodextrin, and
capsaicin in a solution of Tween 80/95% ethanol/saline in a 1/1/8 ratio. Morphine, JNJ and
MPEP were all administered i.p. at a volume of 0.1 mL/100g, whereas capsaicin was
administered locally in the tail at a fixed volume of 0.1 mL. In each of the procedures,
testing at the higher dose combinations of JNJ, MPEP and morphine was limited due to
signs of toxicity, including motor deficits and in one case death.
Data Analysis
For all tests of antinociception and antihyperalgesia, raw latency scores were converted to %
maximum possible effect (%MPE) scores using the following equation:
The %MPE scores from the dose-effect curves examining morphine were used to
mathematically derive the dose of the morphine required to produce a 50% effect (ED50)
either alone or in combination with JNJ or MPEP. Calculation of ED50 values required the
following: 1) an ascending limb of the dose effect curve comprised of at least 3 points and,
2) that the lowest mean %MPE within this limb was ~20% or lower, and the highest mean
%MPE was ~80% or higher. Subsequently, relative potency estimates of morphine alone
were compared to those of morphine when combined with JNJ or MPEP. For this analysis,
dose ratios were calculated by comparison of the slopes of two linear regression lines
representing the two dose-effect curves and the distance between those two lines determined
as described by Tallarida and Murray (1987). In incidences in which the potency ratios
yielded negative values, the order of dose-effect curves inputted into the Tallarida and
Murray program were reversed, thus yielding positive values. All analyses of dose ratios
were conducted using group data. Differences in the relative potency were considered to be
significant if the 95% confidence interval did not overlap 1.0 or below. Additional analyses
were conducted using isobols in which the ED50 dose (95% C.L.) of a drug combination
were compared to the ED50 dose (95% C.L.) of morphine when administered alone (details
are described in the Results section). In the capsaicin procedure, comparisons were made
between a select dose of morphine alone and in combination with JNJ and MPEP using a
one-factor ANOVA. When a significant ANOVA was obtained, a Dunnett’s multiple
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comparison was used to determine the statistical significance of specific dose combinations.
Time course analyses for JNJ and MPEP were analyzed using separate repeated measures
two-way ANOVA (RMANOVA). For all statistical tests, the alpha level was set at P=0.05.
RESULTS
Figure 1 shows the effects of morphine, JNJ and MPEP on the hotplate (left), warm water
tail-withdrawal (middle) and capsaicin (right) procedures. Morphine produced a dose-
dependent increase in antinociception in both the hotplate and warm water tail-withdrawal
procedures, as well as a dose-dependent increase in antihyperalgesia in the capsaicin
procedure. In each of these procedures, morphine produced a maximal effect (100%). Based
on the ED50 values (Table 1), morphine was most potent in the capsaicin procedure (2.51
mg/kg) and least potent in the hotplate (13.27 mg/kg) procedure.
Across the range of doses tested in the hotplate and warm water tail-withdrawal procedures,
JNJ and MPEP produced only low levels of antinociception (maximum: 29%). JNJ failed to
produce an antihyperalgesic effect in the capsaicin procedure, whereas at the highest dose
tested MPEP produced intermediate levels of antihyperalgesia (maximum: 61%). In both the
hotplate and warm water tail-withdrawal procedures, JNJ and MPEP were also evaluated 15
to 60 min after administration (data not shown). Separate RMANOVA of the effects of JNJ
and MPEP in the hotplate procedure and MPEP in the warm water tail-withdrawal procedure
failed to indicate a significant effect of dose, time, or a dose × time interaction. In the warm
water tail-withdrawal procedure, a RMANOVA of the effects of JNJ across the different
time points indicated a significant effect of dose (F2,9=5.8 P<0.05), time (F2,37=4.1 P<0.05),
and dose × time interaction (F6,27=3.7 P<0.05). The maximal level of antinociception
produced by JNJ, however, was only 26%.
Figure 2 shows the effects of morphine alone and in combination with selected doses of JNJ
(left) and MPEP (right) on the hotplate procedure. JNJ produced a dose-dependent leftward
shift in the morphine dose-effect curve, with the highest dose tested decreasing the morphine
ED50 value from 13.27 mg/kg to 1.00 mg/kg (Table 1). Analysis of potency ratios indicated
that this dose of JNJ produced a 12.52-fold leftward shift in the morphine dose-effect curve.
Whereas the two lowest doses of MPEP failed to alter the morphine dose-effect curve, the
highest dose produced a 4.18-fold leftward shift (Table 1). At this dose combination of
MPEP and morphine, a maximal effect was obtained at 10 mg/kg, whereas when
administered alone morphine produced a maximal effect at 30 mg/kg.
Figure 3 shows the effects of morphine alone and in combination with selected doses of JNJ
(left) and MPEP (right) on the warm water tail-withdrawal procedure. At each of the doses
tested, JNJ produced small, leftward shifts in the morphine dose-effect curve (Table 1). The
lowest dose of MPEP failed to alter the morphine curve, the intermediate dose produced a
small rightward shift in the morphine curve, and the highest dose produced a 1.97-fold
leftward shift in the morphine curve. At the highest dose of MPEP, the maximal effect of
morphine was obtained at a dose of 10 mg/kg, whereas when administered alone morphine
produced a maximal effect at 30 mg/kg.
Figure 4 shows an isobolographic analysis of the effects of JNJ and MPEP administered in
combination with morphine in the hotplate (left) and warm water tail-withdrawal (right)
procedures. The effects of JNJ and MPEP are illustrated in both panels of the graph, as
comparisons were made to the same, composite morphine dose-effect curve. As shown in
the left panel, the two highest doses of JNJ (1.0 and 3.0 mg/kg) tested produced supra-
additive effects with morphine, as the ED50 values (and C.L.) fell to the left of the
theoretical line of additivity. As noted previously, these effects were dose-dependent with
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the largest effect obtained at the highest dose of JNJ. Similarly, at the lowest dose of JNJ
(1.0 mg/kg) tested in the warm water tail-withdrawal procedure, the interaction with
morphine was supra-additive, although the magnitude of this effect was considerably
smaller than that obtained in the hotplate procedure. This graphic analysis also indicated that
the interaction with morphine and the highest dose of MPEP (30 mg/kg) was supra-additive
in the hotplate procedure. In the warm water-tail withdrawal procedure, the interaction at the
intermediate dose of MPEP (10 mg/kg) with morphine was antagonistic (i.e., ED50 dose of
morphine was to the right of the line of additivity) and at the highest dose (30 mg/kg) it was
supra-additive.
Figure 5 shows the effects of two doses of morphine alone and in combination with JNJ (top
panels) and MPEP (bottom panels) in the capsaicin procedure. These two doses of morphine
were selected as they produced minimal (1.0 mg/kg) and intermediate (3.0 mg/kg) levels of
antihyperalgesia when administered alone, thus allowing for the identification of potential
enhancement of morphine antihyperalgesia. Separate ANOVAs for 1.0 and 3.0 mg/kg
morphine did not reveal an effect of JNJ on morphine antihyperalgesia. Similarly, MPEP did
not alter the effects of 1.0 mg/kg morphine. In contrast, when MPEP was examined in
combination with 10 mg/kg morphine it attenuated rather than potentiated morphine
antihyperalgesia, with the highest dose (10 mg/kg) decreasing morphine antihyperalgesia
from 65% to 12%. When 10 mg/kg MPEP was administered alone, it produced a 61%
antihyperalgesic effect (see Fig. 1). An ANOVA for 3.0 mg/kg morphine confirmed a main
effect of MPEP dose (F2,22=3.5, P<0.05), with a Dunnett’s multiple comparison indicating a
significant (P<0.05) difference at 10 mg/kg MPEP.
Discussion
The present study compared the effects of the mGluR1 antagonist JNJ and the mGluR5
antagonist MPEP in rat models of acute pain (hotplate, warm water tail-withdrawal) and
persistent, inflammatory pain (capsaicin). In the hotplate and warm water tail-withdrawal
procedures, JNJ and MPEP were ineffective when administered alone. In both of these
procedures, however, JNJ potentiated morphine antinociception. MPEP also potentiated
morphine antinociception in the hotplate procedure, whereas in the warm water tail-
withdrawal procedure it produced a biphasic effect, antagonizing the effects of morphine at
a moderate dose and potentiating morphine antinociception at the highest dose tested.
Finally, in the capsaicin procedure, the highest dose of MPEP alone produced intermediate
levels of antihyperalgesia, and this dose attenuated the effects of the highest dose of
morphine examined. In contrast, no dose of JNJ had an effect when administered alone in
this procedure nor did JNJ alter morphine-induced antihyperalgesia.
In both of the acute pain models examined, MPEP potentiated morphine antinociception.
This finding contrasts with those reported in a mice tail-flick procedure, in which MPEP had
no effect on morphine antinociception (Kozela et al., 2003; Fischer et al., 2008b). As such,
the present finding are the first to establish that MPEP can enhance morphine
antinociception and thus extends previous studies indicating an interaction between
morphine and MPEP. Indeed, MPEP has been shown to attenuate the development of
tolerance to morphine antinociception (Kozela et al., 2003) and inhibit the acquisition of
morphine conditioned place preference (Popik and Wrobel, 2002).
It is important to note, however, that the potentiation of morphine antinociception by MPEP
in the present investigation was obtained only at a relatively high dose (30 mg/kg).
Similarly, other studies report that MPEP/morphine interactions are most evident at
relatively high doses of MPEP (Popik and Wrobel, 2002; Kozela et al., 2003), and there is
evidence that these high doses display activity at the NMDA receptors (Cosford et al., 2003;
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Lea and Faden, 2006). Since NMDA receptor antagonists potentiate morphine
antinociception under a range of conditions (e.g., Nemmani et al., 2004; Fischer et al.,
2008a), it is possible that in the present study the effects of MPEP were mediated by activity
at the NMDA receptor site.
The effects of MPEP were also examined in a rat model of persistent, inflammatory pain in
which local administration of capsaicin into the tail induces a hyperalgesic response to non-
noxious 45°C water. In this procedure, the highest dose MPEP produced intermediate levels
of antihyperalgesia when administered alone, a finding in agreement with studies indicating
that mGluR5 antagonists produce antihyperalgesic effects in a variety of inflammatory pain
models (Walker et al., 2001a,b; Zhu et al., 2004; Lee et al., 2006; Sevostianova and Danysz,
2006; Jesse et al., 2008) and can reduce the development of capsaicin-induced mechanical
allodynia (Soliman et al., 2004). When administered in combination with morphine in the
capsaicin procedure, however, MPEP produced dose-dependent decreases in morphine
antihyperalgesia. That MPEP could produce antihyperalgesia in this model and attenuate the
antihyperalgesic effects of morphine suggests a mutual antagonism. Such effects have not
been reported with other mGluR antagonists and morphine, thus the mechanism underlying
this phenomenon has not been systematically studied.
Recent studies indicate that MPEP decreases mu opioid receptor (MOR) phosphorylation,
internalization, and desensitization in HEK293 cells co-expressing mGluR5 and MOR
(Schröder et al., 2009). These processes may alter the availability of MOR to its ligands, an
effect which may alter the antinociceptive efficacy of mu opioid agonists. Consequently, if
the number of MORs available to morphine is decreased by MPEP, then the number of
MORs occupied by morphine likewise should be decreased. It is thus possible that under the
inflammatory conditions, MPEP may have decreased MOR availability, thereby attenuating
morphine antihyperalgesia.
In contrast to the effects produced by MPEP, JNJ produced large dose-dependent increases
in morphine antinociception in the hotplate procedure and small increases in the warm water
tail-withdrawal procedure. Similarly, Fischer et al., (2008b) reported that JNJ potentiated the
antinociceptive effects of morphine in a mouse tail-flick procedure. As mGlu1 receptors are
expressed postsynaptically on dorsal horn neurons (Jia et al., 1999; Alvarez et al., 2000) and
potentiate NMDA-mediated responses in this region (Kelso et al., 1992; Skeberdis et al.,
2001), it is possible that these effects are mediated by activity at the NMDA receptor site.
When administered alone, JNJ failed to attenuate antihyperalgesia in the capsaicin
procedure. Whereas this finding is in agreement with studies indicating that mGluR1
antagonists are not active in some inflammatory pain models (Walker et al., 2001a; Lee et
al., 2006), it contrasts with those indicating that mGluR1 antagonists produce hyperalgesia
in both inflammatory and non-inflammatory pain models (Sevostianovaa and Danysz, 2006;
Kohara et al., 2007; Siniscalcoa et al., 2008). For example, the non-competitive mGluR1
antagonist, A-841720, reduced thermal nociceptive responses in a persistent model of
inflammatory pain induced by injections of Freund’s adjuvant as well as mechanical
nociception in a neuropathic pain model (but see Fundytus et al., 2001; El-Kouhen et al.,
2006). It is important to note that when antihyperalgesic effects are observed following the
administration of mGluR1 antagonists, the magnitude of these effects are typically small and
not always dose-dependent. Differences across persistent pain models also have been
reported with NMDA antagonists (e.g., Sakurada et al., 1998; Lomas et al., 2008), and some
of these discrepancies may be related to the mechanism underling the production of
persistent or chronic pain. For example, nociception in the capsaicin procedure is mediated
primarily by activity at neurokinin receptors (Lao et al., 2003), whereas in a number of other
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inflammatory (e.g., Freund, formalin) and non-inflammatory pain models (e.g., neuropathic)
NMDA receptor mediation plays a prominent role (e.g., Mao et al., 1992).
In contrast to the effects obtained when JNJ was administered in combination with morphine
in the hotplate and warm water-tail withdrawal procedures, JNJ had no effect on morphine
antihyperalgesia when evaluated in the capsaicin procedure. As there are no reports
describing the effects of JNJ or other mGluR1 antagonists on morphine antihyperalgesia in
chronic pain models, the specificity of these findings remains to be determined.
Nevertheless, the differences observed across pain models with JNJ clearly establish the
importance of pain model when assessing the interaction between morphine and mGluR1
antagonists, and thus parallel the results obtained with MPEP and various NMDA
antagonists (e.g., Nemmani et al., 2004; Lomas et al., 2008).
Recent findings suggest that combinations of morphine and NMDA antagonists may have
some clinical utility, as it has been postulated that NMDA antagonists could reduce the
required dose of morphine, inhibit the development of morphine tolerance, and produce
fewer side effects than high dose morphine therapy. The utility of these combinations is
limited, however, by findings that NMDA antagonists produce a range of side effects.
Moreover, the clinical data have been conflicting, with NMDA antagonists enhancing
analgesia in some studies of cancer pain (Katz, 2000) but not in studies of chronic, non-
neuropathic pain (Galer et al., 2005). Since activation of mGlu receptors enhance NMDA-
mediated activity (Kelso et al., 1992; Skeberdis et al., 2001), it has been proposed that
mGluR antagonists might have some clinical utility in the treatment of pain as well.
Evaluating this proposal has recently been initiated, with studies emphasizing involvement
of mGluR subtypes and the specificity of their effects across different pain models.
One of the problems in assessing the potential clinical effectiveness of combinations of
mGluR antagonist and morphine is that pain is not a unitary phenomenon and different types
of pain (post-surgical, inflammatory, neuropathic) respond to different classes of drugs or
drug combinations. Moreover, it is well established that pain can differ along a number of
critical dimensions, including the duration of nociception, type of nociceptive stimulus,
fibers underlying the nociceptive response, and mediation by distinct excitatory amino acids
and neurotransmitter systems. The present findings illustrate this complexity, as the effects
produced by MPEP and JNJ in a persistent pain model (capsaicin) contrast markedly with
those obtained in acute pain models (hotplate, warm water tail-withdrawal). MPEP, for
example, enhanced morphine antinociception in both acute pain models, but attenuated
morphine antihyperalgesia in the persistent pain model. Further, a comparison across the
acute pain models indicated that the effects produced by both MPEP and JNJ were
considerably larger in the hotplate than the warm water tail procedure. Such findings suggest
that medication development for the treatment of pain should include a diverse set of pain
models, including multiple acute or chronic pain models believed to be predictors of the
effectiveness of analgesics against a specific type of pain.
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Effects of morphine, JNJ and MPEP administered systemically on the hotplate (left), warm
water tail-withdrawal (center) and capsaicin procedures (right). Morphine was determined
on the hotplate and warm water tail-withdrawal procedures using a cumulative dosing
procedure, whereas all other tests were conducted using an acute dosing procedure in which
drugs were administered 30 mins prior to testing. In the hotplate, warm water tail-
withdrawal, and capsaicin procedures, morphine was tested in 16 rats, JNJ in 4–6 rats, and
MPEP in 4 rats, respectively. Vertical axis: antinociception expressed as the % of maximal
possible effect in the hotplate and warm water tail-withdrawal procedures, and
antihyperalgesia expressed as the % of maximal possible effect in the capsaicin procedure.
Horizontal axis: dose of morphine, JNJ or MPEP expressed in mg/kg. Vertical bars represent
the standard error; where not indicated, the standard error fell within the data point.
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Effects of morphine administered alone and in combination with JNJ (left) and MPEP (right)
on the hotplate procedure. Morphine alone was tested in 16 rats and in combination with the
different doses of JNJ in 4–6 rats and MPEP in 4–7 rats. Vertical axis: antinociception
expressed as the % of maximal possible effect. Horizontal axis: dose of morphine
determined using a cumulative dosing procedure and expressed in mg/kg. Vertical bars
represent the standard error; where not indicated, the standard error fell within the data
point.
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Effects of morphine administered alone and in combination with JNJ (left) and MPEP (right)
on the warm water tail-withdrawal procedure. Morphine alone was tested in 16 rats and in
combination with the different doses of JNJ in 4–8 rats and MPEP in 4–7 rats. Vertical axis:
antinociception expressed as the % of maximal possible effect. Abscissa: dose of morphine
determined using a cumulative dosing procedure and expressed in mg/kg. Vertical bars
represent the standard error; where not indicated, the standard error fell within the data
point.
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Isobolograms for morphine in combination with JNJ and MPEP on the hotplate (left) and
warm water tail-withdrawal (right) procedures. The effects of JNJ and MPEP are illustrated
in each panel of the graph, as comparisons were made to a single morphine curve in the
hotplate procedure and a single morphine curve in warm water tail-withdrawal procedure.
Horizontal axis: ED50 value (95% C.L.) for morphine expressed in mg/kg. The
perpendicular line intersecting the morphine ED50 value represents the theoretical line of
additivity. Vertical axis: dose of JNJ or MPEP, expressed in mg/kg, administered in
combination with a morphine dose-effect curve. Vertical lines represent the 95% C.L. of the
ED50 values for morphine: when the ED50 was to the left of the theoretical line of additivity
and the C.L. lines did not overlap the shaded area, the interaction was considered to be
supra-additive, whereas when the C.L. lines did overlap with the shaded area, the interaction
was considered additive.
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Effects of selected doses of morphine administered alone and in combination with JNJ (top
panels) and MPEP (bottom panels) in the capsaicin procedure. These two doses of morphine
were selected as they produced minimal (1.0 mg/kg: left most panels) and moderate (3.0 mg/
kg: right most panels) antihyperalgesic effects when administered alone, thus allowing for
the identification of potential enhancement of morphine antihyperalgesia. Morphine alone
was tested in 11–13 rats, in combination with the two lower doses of JNJ and MPEP in 4–8
rats: due to toxic effects, dose combinations with the highest dose of JNJ and MPEP with
morphine were limited to 2–4 rats. Vertical axis: antihyperalgesia expressed as the % of
maximal possible effect. Horizontal axis: doses of morphine alone and in combination with
JNJ or MPEP determined using an acute dosing procedure and expressed in mg/kg. Vertical
bars represent the standard error: asterisks indicate a significant (P<0.05) difference from
morphine alone.
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TABLE 1
ED50 values (95% confidence limits) and relative potency ratios (95% confidence limit) for morphine alone
and in combination with JNJ or MPEP in the hotplate, warm water tail-withdrawal and capsaicin procedures.
ED50 (95% C.L.) Potency Ratioa
Hotplate:
       Morphine alone: 13.27 (11.15 – 15.80)
       + 0.3 JNJ 8.35 (5.59 – 12.44) −1.59 (1.12 – 2.25)*
       + 1.0 JNJ 3.31 (2.18 – 5.02) −4.27 (3.05 – 5.97)*
       + 3.0 JNJ 1.00 (0.58 – 1.74) −12.52 (8.32 – 18.84)*
       + 3.0 MPEP 13.57 (9.79 – 18.84)   1.04 (0.79 – 1.37)
       + 10 MPEP 12.89 (10.37 – 16.05) −1.07 (0.79 – 1.44)
       + 30 MPEP 3.28 (1.97 – 5.45) −4.18 (2.82 – 6.19)*
Warm Water Tail-Withdrawal:
       Morphine alone: 6.90 (5.55 – 8.59)
       + 1.0 JNJ 3.74 (1.28 – 5.04) −1.85 (1.28 – 2.67)*
       + 3.0 JNJ 4.46 (2.56 – 7.77) −1.77 (1.10 – 2.86)*
       + 5.6 JNJ 4.35 (3.02 – 6.25) −1.59 (1.01 – 2.50)*
       + 3.0 MPEP 8.71 (6.91 – 10.96)   1.25 (0.88 – 1.76)
       + 10 MPEP 13.20 (10.61 – 16.42)   1.88 (1.29 – 2.75)**
       + 30 MPEP 3.51 (2.83 – 4.35) −1.97 (1.32 – 2.97)*
Capsaicin:
       Morphine alone: 2.51 (2.13 – 4.35)
CL, confidence limit
a
negative numbers indicate a leftward shift in the morphine dose-effect curve, positive numbers a rightward shift
*
more potent (P<0.05) than morphine alone in each respective procedure
**
less potent (P<0.05) than morphine alone in each respective procedure
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